KPV

KPV is a tripeptide: lysine, proline, valine. Those three amino acids are the final segment of α-MSH, the hormone best known for instructing pigment cells to make melanin. Cut them off and study them alone, and the pigmentation activity disappears while an anti-inflammatory effect remains.

This is the interesting result, because it means the two activities live in different parts of the molecule. Pigmentation requires the core sequence that the melanocortin receptors read. The anti-inflammatory action does not appear to depend on those receptors at all, which is why a fragment with no pigment activity still does something.

Its size is the other distinguishing feature. At three amino acids KPV is small enough to be taken up by transporters intended for the products of protein digestion — in particular one abundant in the lining of the intestine. A molecule that can use a nutrient transporter to enter cells is in a different practical position from one that must find a receptor on the surface.

• Activity without the receptor: It appears to act without engaging melanocortin receptors, which means it is doing something inside the cell rather than signalling from outside — unusual for a peptide fragment.

• NF-κB signalling: Published work concentrates on a master switch controlling inflammatory gene expression. Acting on that switch, rather than on one inflammatory molecule, is what makes the effect broad.

• Entry through a nutrient transporter: Intestinal cells carry a transporter for short peptides from digested food, and this one is small enough to use it — a route into the cell that most peptides cannot take.

• Intestinal inflammation models: Rodent colitis studies are the main experimental context, chosen because that is where the transporter is most abundant and the delivery argument is strongest.

Inflammation is a coordinated programme, not a single event. When a cell detects damage or infection it switches on dozens of genes at once — signalling molecules, adhesion proteins, enzymes — and that switching is largely controlled by a protein complex called NF-κB. In a resting cell NF-κB is held in the cytoplasm by an inhibitor. When an inflammatory signal arrives the inhibitor is destroyed, NF-κB moves into the nucleus, and the programme starts.

Most anti-inflammatory compounds act on one output of that programme — a single enzyme or a single messenger. Acting on the switch instead affects the whole set. Published work on KPV concerns this level: it is reported to interfere with NF-κB reaching the nucleus, so the programme is dampened rather than one of its products blocked.

For that to be possible the peptide has to get inside the cell, which is where its size matters. The intestinal lining carries PepT1, a transporter that absorbs di- and tripeptides from digested protein. A tripeptide can use it, and once inside, a small molecule can interfere with a process that surface receptors never reach. This is why the gut is the setting for most of the published work rather than an arbitrary choice of tissue.

The cell and animal work is genuine and independently published. Rodent colitis models have shown reduced inflammatory markers, the NF-κB connection is supported by multiple studies, and transporter-mediated uptake in intestinal cells has been demonstrated directly.

There are no clinical trials and no approved use, and it is supplied for laboratory research only. Whether a tripeptide reaches useful concentrations away from the gut is an open question. Its mechanism is unusually well characterised for a fragment of this size — uptake through a nutrient transporter, and an effect on the switch that controls inflammatory gene expression as a set.

LL-37 is the opposite kind of immune peptide — large, membrane-active, and working from outside the cell rather than inside it. The contrast between a 37-residue amphipathic helix and a tripeptide is the clearest illustration of how varied this category is.

KLOW Stack includes KPV alongside other peptides in a single preparation, and VIP is another compound studied for inflammation in intestinal tissue through an entirely different route.